N/A N=86 Safety and Effectiveness Clinical Evaluation of Injectable Medical Devices Viscol
Aesthetic Dermatology
Primary: Performance at 1 Month Investigator Overall VISCOL Range — 77 Participants — p=<0.0001
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=55 Effects of Pioglitazone on Stress Reactivity and Alcohol Craving
Alcohol Use Disorder
Primary: Change in Stress-reactivity as Assessed by Heart Rate Change During the Cold Pressor Task (CPT) — 5.138; 12.154 beats per minutes (bpm)
N/A N=253 Pain Research: Innovative Strategies With Marijuana
Chronic Pain · Chronic Low Back Pain · Cannabis Use
Primary: Pain Interference: Roland Morris Disability Questionnaire (RMDQ) — 8.028; 9.635; 9.034; 6.194 score on a scale
N/A N=2,860 Ventilation Strategy During General Anesthesia for Orthopedic Surgery: A Quality Improvement Project
Orthopedic Surgery · Ventilation
Primary: Time-weighted Average SaO2/FiO2 Ratio in the Postanesthesia Care Unit (PACU) — 355; 350; 353; 352 ratio — p=0.042
Phase 3 N=711 Study to Evaluate the Efficacy and Safety of AZD4831 in Participants With Heart Failure With Left Ventricular Ejection Fraction > 40%
Heart Failure With Preserved Ejection Fraction
Primary: Kansas City Cardiomyopathy Questionnaire -Total Symptom Score — 10.70; 9.81; 11.62 Points — p=0.537
N/A N=10,256 Symptom Management Implementation of Patient Reported Outcomes in Oncology
Other Cancer · Gastrointestinal Cancer · Thoracic Cancer
Primary: Emergency Department Treat/Release [EDTR] Event Occurrence Status at Day 30 — 5.8; 6.9; 5.3; 5.8 percentage of patients with event — p=0.214
N/A N=29 A Personalized Self-care Support Program for Primary Care Patients With Diabetic Foot Ulcer
Foot Ulcer
Primary: Feasibility of Recruiting and Retaining — 26 Participants
N/A N=34 DMID 21-0041; Influenza CVD 59000
Influenza
Primary: Viral Confirmation — 6; 0 Participants
N/A N=142 Delayed Sleep Timing in Teens Study
Delayed Sleep Phase
Primary: Weekday Sleep Duration - Actigraphy — 6.309; 5.866; 5.880; 5.845 Number of hours — p=0.018
Phase 2 N=29 A Study of ANV419 Alone or in Combination With Approved Treatment in Patients With Cutaneous Melanoma (OMNIA-1).
Melanoma (Skin) · Cutaneous Melanoma · Adult Disease
Primary: Monotherapy Dose Expansion: Objective Response Rate (ORR) as Defined by RECIST v1.1 — 0; 0 Participants
N/A N=62 Effects of Low-calorie Sweetened Beverage Restriction in Youth With Type 1 Diabetes
Type 1 Diabetes
Primary: Glycemic Variability — 2.00; 3.91 percent
N/A N=1,044 Building Infrastructure for Community Capacity in Accelerating Integrated Care
Mental Health
Primary: Engagement in Mental Health Intervention Sessions — 464 Participants
Phase 3 N=6,016 Study to Evaluate the Efficacy (Effect on Disease) and Safety of Finerenone in Participants With Heart Failure and Left Ventricular Ejection Fraction (Proportion of Blood Expelled Per Heart Stroke) Greater or Equal to 40%
Heart Failure
Primary: Occurrence of the Composite Endpoint of Cardiovascular Death and Total (First and Recurrent) Heart Failure Events — 1083; 1283 events — p=0.0072
N/A N=57,837 INSPIRE Trial for Skin and Soft Tissue Infections
Skin and Soft Tissue (SST) Infection
Primary: Extended-Spectrum Days of Antibacterial Therapy (ES-DOT) Per Empiric Day — 43305; 40156; 43927; 30287 Extended-Spectrum Days-of-Therapy
N/A N=57 Investigating Hearing With Ponto 3 SuperPower, a Bone Anchored Hearing Aid - Investigating Hear
Hearing Loss, Conductive · Hearing Loss Mixed · Hearing Disability
Primary: Change in Functional Gain Thresholds: Unaided Air Conduction (AC) Thresholds Compared to Aided Bone Conduction (BC) Thresholds, in Ponto 3 SuperPower Users With…